VA
VIR icon

Vident Advisory’s Vir Biotechnology VIR Stock Holding History

Vident Advisory’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,419
Closed -$155K – 1564
2024
Q2 		$155K Buy
17,419
+5,391
+45% +$51.7K ﹤0.01% 1319
2024
Q1 		$122K Buy
+12,028
New +$122K ﹤0.01% 1276

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vident Advisory's VIR Position: Q3 2024 in Review

Vident Advisory sold out of Vir Biotechnology (VIR) in Q3 2024, closing a stake of 17,419 shares — an estimated $155K sold.

Vident Advisory first reported a position in VIR in Q1 2024 and held it in 2 quarters. The position peaked at $155K in Q2 2024. 197 funds tracked by Wall St. Rank hold VIR as of Q3 2024.

  • Vident Advisory reported no remaining Vir Biotechnology position as of Q3 2024 after selling out during the quarter.
  • Vident Advisory sold 17,419 Vir Biotechnology shares in Q3 2024, an estimated $155K.
  • Vident Advisory first reported a position in Vir Biotechnology in Q1 2024 and held it in 2 quarters.
  • Vident Advisory's Vir Biotechnology position peaked at $155K in Q2 2024.
  • 197 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2024.

Based on Vident Advisory's 13F filing for Q3 2024, filed 14 Nov 2024.